Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While financial performance shows growth, the decline in GAAP net income and EPS, alongside high operating expenses, raises concerns. The positive shareholder return plan and acquisition strategy are offset by competitive pressures and economic uncertainties highlighted in the Q&A. The market cap suggests moderate volatility, but the lack of clear guidance on key strategic initiatives tempers expectations. Overall, the sentiment is neutral given the balanced positives and negatives.
Key Financial Performance
Net Product Revenues $177.8 million, up 23% year-over-year.
Jornay Net Revenue $28.5 million, representing a 24% year-over-year growth in prescriptions.
Belbuca Net Revenue $51.7 million, up 2% year-over-year.
Xtampza Net Revenue $47.6 million, up 4% year-over-year.
Nucynta Franchise Net Revenue $47.1 million, up 4% year-over-year.
GAAP Operating Expenses $75.6 million, up 80% year-over-year due to ongoing costs to commercialize Jornay and targeted investments.
Non-GAAP Adjusted Operating Expenses $62.2 million, up 80% year-over-year for similar reasons as GAAP operating expenses.
GAAP Net Income $2.4 million, down from $27.7 million year-over-year due to acquisition-related expenses.
Non-GAAP Adjusted EBITDA $95.2 million, up 3% year-over-year.
GAAP Earnings Per Share $0.08 basic and $0.07 diluted, down from $0.86 basic and $0.71 diluted year-over-year.
Non-GAAP Adjusted Earnings Per Share $1.49, up from $1.45 year-over-year.
Cash from Operations $55.4 million.
Cash Position $197.8 million, up $35 million from year-end.
Net Leverage 1.5x net debt to EBITDA.
Debt Repayment $16.1 million repaid this quarter, with an additional $48.4 million expected to be repaid during the remainder of 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Jornay PM Revenue: Jornay PM generated $28.5 million in net revenue, with a 24% year-over-year growth in prescriptions.
Pain Portfolio Revenue: The pain portfolio generated $149.2 million in sales, up 3% year-over-year.
Market Share: Jornay's market share of the long-acting branded methylphenidate market increased to 20.3%, up 6.4% year-over-year.
Sales Force Expansion: Collegium expanded its sales force for Jornay by adding approximately 55 new representatives, bringing the total to about 180.
Cash Flow Generation: Generated $55.4 million in cash from operations, increasing cash position to nearly $200 million.
Debt Repayment: Paid down $16.1 million of debt in the first quarter.
Share Repurchase Program: Authorized a $25 million accelerated share repurchase program.
Leadership Changes: Announced updates to the executive leadership team and Board of Directors.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercialization Risks: There are risks associated with the successful commercialization of products, which may incur significant expenses and may not prevail in current or future litigation.
Regulatory Risks: The company faces uncertainties related to regulatory approvals and compliance, which could impact product launches and market access.
Competitive Pressures: The ADHD market is highly competitive, with pressures from generic drugs and the need for effective marketing strategies to maintain market share.
Economic Factors: Broader political and economic pressures within the healthcare sector may impact business operations and financial performance.
Supply Chain Challenges: While the company does not expect recent tariffs to materially impact its business, any future supply chain disruptions could affect product availability.
Operational Costs: Significant increases in operating expenses, particularly related to the commercialization of Jornay, could impact profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Priorities: Collegium has three strategic priorities: drive significant growth in Jornay PM, maximize the value of the pain portfolio, and strategically deploy capital to enhance shareholder value.
Sales Force Expansion: Collegium expanded its Jornay sales force by adding approximately 55 new representatives, bringing the total to about 180.
Leadership Changes: Updates to the leadership team and Board of Directors were announced, including new appointments to strengthen the company’s strategic direction.
Share Repurchase Program: The Board authorized a $25 million accelerated share repurchase program to return value to shareholders.
Market Positioning: Collegium aims to be a leader in responsible pain management and has begun diversifying its portfolio beyond pain management.
2025 Revenue Guidance: Collegium expects net product revenues in the range of $735 million to $750 million, an 18% increase year-over-year.
Jornay Revenue Expectations: Jornay is expected to generate net revenue in excess of $135 million, representing at least 34% annual growth from 2024.
Adjusted EBITDA Guidance: Adjusted EBITDA is expected to be in the range of $435 million to $450 million, representing 10% growth year-over-year.
Operating Expenses Guidance: Adjusted operating expenses are expected to be in the range of $220 million to $230 million, reflecting targeted investments for growth.
Debt Repayment: Collegium expects to repay an additional $48.4 million of its term loan during the remainder of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Accelerated Share Repurchase Program: The Board has authorized a $25 million accelerated share repurchase program, reinforcing the commitment to return value to shareholders.
Total Share Repurchase Program: This is part of a larger $150 million share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How would you expect the Jornay scripts to trend before the new kind of season pick-up given the recent investment in the sales force?
A:There is an overall seasonality in the marketplace. As we approach the end of May and June, there may be a slight slowing of scripts due to summer holidays, followed by an acceleration in the back-to-school season around mid-August.
Q:Is the sales force expansion about increasing touch points or geographic expansion?
A:The expansion includes both increasing the target universe from 17,000 to 21,000 healthcare professionals and increasing the frequency of contact with current targets.
Q:Is there an opportunity to utilize the Jornay PM delayed release technology for additional compounds like Adderall or Modafinil?
A:Conversations about using the technology for other compounds occurred even before the acquisition, and it worked well for methylphenidate.
Q:What’s the appetite for a deal in business development given the current environment?
A:We look at capital deployment strategically and will pursue business development if it’s the right time and deal, while also paying down debt and returning value to shareholders.
Q:Can you remind us what the overall ADHD market growth has been recently?
A:The ADHD market is growing at about 5% to 6% overall.
Q:What is the breakdown in the prescriber base between pediatricians and psychiatrists?
A:Roughly 40% is pediatricians, 40% is neuropsychiatrists, and the remaining 20% is split between PCPs and mid-levels.
Q:Where is the market share growth coming from?
A:The growth is primarily coming from the movement from generic immediate release products to branded products.
Q:How large of a sales organization at steady state are you contemplating for Jornay PM?
A:The current sales force of 180 is sized appropriately for the target audience and will be evaluated regularly.
Q:What kind of peak sales range do you think is realistic for Jornay PM?
A:We have not discussed peak sales externally as we want to see the impact of the expansion first.
Q:How large of a transaction could you contemplate given the current state of the capital structure?
A:We have the capacity to do a meaningful transaction if the right opportunity arises, with a potential leverage of up to 3x for a commercial asset.
Q:Review of Unclear Management Responses
A:Management did not provide a specific answer regarding the likelihood of getting a deal done in the current market environment, stating they would not comment specifically on that.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chairman
Directors
Executive Vice
General
Xtampza Nucynta
ability cash
adoption
advance
awareness
capital value
control
day
differentiation favorability
durability pain
expansion sale
fact
force representative
healthcare provider
increase
investment
leader pain
marketing effort
medicine digit
medicine evening
opioid
opportunity portfolio
ownership
oxycodone medicine
pain medicine
patient caregiver
portfolio medicine
prescription pain
priority
product differentiation
remainder
request
research
school
success update
tariff
technology
term product
vision
COLL Transcript
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Positive11-6
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call shows strong financial performance with record revenue growth and optimistic guidance, particularly for Jornay PM. The new $150 million share repurchase program and debt repayment plan further enhance investor confidence. Despite increased operating expenses, the company's strategic focus on expanding market reach and awareness, especially among adults, is promising. The Q&A session did not reveal significant risks, and analysts seemed satisfied with management's responses. Considering the company's small-cap status, the positive developments are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents a mixed outlook. While financial performance shows growth, the decline in GAAP net income and EPS, alongside high operating expenses, raises concerns. The positive shareholder return plan and acquisition strategy are offset by competitive pressures and economic uncertainties highlighted in the Q&A. The market cap suggests moderate volatility, but the lack of clear guidance on key strategic initiatives tempers expectations. Overall, the sentiment is neutral given the balanced positives and negatives.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call Transcript
Unknown2-28
The earnings call presents a mixed picture: strong revenue growth and a robust share repurchase program are positives, but increased operational costs, economic pressures, and lackluster synergy realization pose challenges. The Q&A session highlights uncertainties about future synergies and market dynamics. Despite a solid financial performance, the lack of clear guidance on key issues tempers optimism. Considering the company's small-cap status, the stock price is likely to remain stable, with potential fluctuations balanced by both positive and negative factors.
COLL Slides
COLL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
